From Wikipedia, the free encyclopedia
Pegargiminase
Clinical data
Other namesADI-PEG20
Identifiers
CAS Number
PubChem SID
DrugBank
UNII
ChEMBL

Pegargiminase (also know as pegylated arginine deiminase) is an investigational drug used in arginine deprivation therapy for treating cancers deficient in argininosuccinate synthetase 1 (ASS1). [1] [2] [3] [4] It is a recombinant form of the enzyme arginine deiminase cloned from the bacteria Mycoplasma hominus and synthesized in Escherichia coli. It has been pegylated to improve the half-life and reduce immunogenicity. [1]

References

  1. ^ a b Feun L, Savaraj N (July 2006). "Pegylated arginine deiminase: a novel anticancer enzyme agent". Expert Opinion on Investigational Drugs. 15 (7): 815–22. doi: 10.1517/13543784.15.7.815. PMC  3086545. PMID  16787144.
  2. ^ Kuo MT, Savaraj N, Feun LG (August 2010). "Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes". Oncotarget. 1 (4): 246–51. doi: 10.18632/oncotarget.135. PMC  2998341. PMID  21152246.
  3. ^ Synakiewicz A, Stachowicz-Stencel T, Adamkiewicz-Drozynska E (November 2014). "The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials". Expert Opinion on Investigational Drugs. 23 (11): 1517–29. doi: 10.1517/13543784.2014.934808. PMID  24965808.
  4. ^ Field GC, Pavlyk I, Szlosarek PW (February 2023). "Bench-to-Bedside Studies of Arginine Deprivation in Cancer". Molecules. 28 (5). Basel, Switzerland: 2150. doi: 10.3390/molecules28052150. PMC  10005060. PMID  36903394.
From Wikipedia, the free encyclopedia
Pegargiminase
Clinical data
Other namesADI-PEG20
Identifiers
CAS Number
PubChem SID
DrugBank
UNII
ChEMBL

Pegargiminase (also know as pegylated arginine deiminase) is an investigational drug used in arginine deprivation therapy for treating cancers deficient in argininosuccinate synthetase 1 (ASS1). [1] [2] [3] [4] It is a recombinant form of the enzyme arginine deiminase cloned from the bacteria Mycoplasma hominus and synthesized in Escherichia coli. It has been pegylated to improve the half-life and reduce immunogenicity. [1]

References

  1. ^ a b Feun L, Savaraj N (July 2006). "Pegylated arginine deiminase: a novel anticancer enzyme agent". Expert Opinion on Investigational Drugs. 15 (7): 815–22. doi: 10.1517/13543784.15.7.815. PMC  3086545. PMID  16787144.
  2. ^ Kuo MT, Savaraj N, Feun LG (August 2010). "Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes". Oncotarget. 1 (4): 246–51. doi: 10.18632/oncotarget.135. PMC  2998341. PMID  21152246.
  3. ^ Synakiewicz A, Stachowicz-Stencel T, Adamkiewicz-Drozynska E (November 2014). "The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials". Expert Opinion on Investigational Drugs. 23 (11): 1517–29. doi: 10.1517/13543784.2014.934808. PMID  24965808.
  4. ^ Field GC, Pavlyk I, Szlosarek PW (February 2023). "Bench-to-Bedside Studies of Arginine Deprivation in Cancer". Molecules. 28 (5). Basel, Switzerland: 2150. doi: 10.3390/molecules28052150. PMC  10005060. PMID  36903394.

Videos

Youtube | Vimeo | Bing

Websites

Google | Yahoo | Bing

Encyclopedia

Google | Yahoo | Bing

Facebook